Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose secukinumab plus methotrexate for moderate to severe plaque psoriasis
ChiCTR2100041703Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of secukinumab and methotrexate in plaque psoriasis, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: PASI75 response rate at week 12. Started Jan 2021; status: recruiting.
02
Drugs
secukinumabmethotrexate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2100041703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041703.